sickle cell disease Archives -

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Vertex Pharma and partner CRISPR Therapeutics will start a rolling marketing application in the US for their gene-editing

Vertex, CRISPR prep filing for gene-editing blood disorder therapy

https://pharmaphorum.com/news/vertex-crispr-prep-filing-for-gene-editing-blood-disorder-therapy/

News/ News/ Sales and Marketing

Novo Nordisk steps up sickle cell push with $1.1bn Forma buy

Phil Taylor Forma Therapeutics, Haematology, M&A, Novo Nordisk, sickle cell disease, thalassaemia 0 Comment

Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion

Novo Nordisk steps up sickle cell push with $1.1bn Forma buy

https://pharmaphorum.com/news/novo-nordisk-steps-up-sickle-cell-push-with-1-1bn-forma-buy/

News/ News/ Sales and Marketing

Pfizer vaults into sickle cell market as GBT deal confirmed

Phil Taylor Global Blood Therapeutics, M&A, Oxbryta, Pfizer, sickle cell disease 0 Comment

Pfizer’s reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the

Pfizer vaults into sickle cell market as GBT deal confirmed

https://pharmaphorum.com/news/pfizer-vaults-into-sickle-cell-market-as-gbt-deal-confirmed/

News/ News/ Sales and Marketing

Pfizer bid for sickle cell drug developer GBT said to be imminent

Phil Taylor Global Blood Therapeutics, M&A, Oxbryta, Pfizer, sickle cell disease 0 Comment

Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT) and its oral

Pfizer bid for sickle cell drug developer GBT said to be imminent

https://pharmaphorum.com/news/pfizer-bid-for-sickle-cell-drug-developer-gbt-said-to-be-imminent/

News/ News/ R&D

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

Phil Taylor beta thalassaemia, gene editing, Haematology, Novartis, partnering, Precision BioSciences, sickle cell disease 0 Comment

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

https://pharmaphorum.com/news/precision-bio-climbs-on-near-1-5bn-sickle-cell-pact-with-novartis/

News/ News/ R&D

EHA: Vertex, CRISPR build case for gene-editing drug

Phil Taylor beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, EHA 2022, gene editing, sickle cell disease, Vertex Pharma 0 Comment

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical

EHA: Vertex, CRISPR build case for gene-editing drug

https://pharmaphorum.com/news/eha-vertex-crispr-build-case-for-gene-editing-drug/

Market Access/ News/ News

GBT claims EU approval for sickle cell drug Oxbryta

Phil Taylor EU, Global Blood Therapeutics, Oxbryta, regulatory approval, sickle cell disease 0 Comment

Global Blood Therapeutics’ run of positive regulatory news for its oral sickle cell disease treatment Oxbryta has continued

GBT claims EU approval for sickle cell drug Oxbryta

https://pharmaphorum.com/news/gbt-claims-eu-approval-for-sickle-cell-drug-oxbryta/

Patients/ Views & Analysis/ Views and analysis

‘Build back better’ cannot mean longer waiting times for change

mike.hammerton@pharmaphorum.com Global Blood Therapeutics, Nigel Nicholls, sickle cell disease 0 Comment

Global Blood Therapeutics (GBT) UK general manager Nigel Nicholls discusses the impact of COVID-19 for sickle cell patients

‘Build back better’ cannot mean longer waiting times for change

https://pharmaphorum.com/patients/covid-sickle-cell-nhs-impact/

Market Access/ News/ News

Joy as sickle cell patients get access to Novartis’ Adakveo after NICE ruling

Phil Taylor Adakveo, Haematology, HEOR, market access, NICE, Novartis, rare disease, sickle cell disease 0 Comment

People living with sickle cell disease (SCD) in England and Wales will be able to get access to

Joy as sickle cell patients get access to Novartis’ Adakveo after NICE ruling

https://pharmaphorum.com/news/joy-as-sickle-cell-patients-get-access-to-novartis-adakveo-after-nice-ruling/

Trending

sickle cell disease

Login